Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Merus N.V. (MRUS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, between Merus N.V. and Jefferies LLC, BofA Securities, Inc., Guggenheim Securities, LLC and William Blair & Company, L.L.C., as representatives of the underwriters named therein",
"Opinion of NautaDutilh N.V"
05/23/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
04/17/2023 8-K Quarterly results
01/09/2023 8-K Investor presentation
Docs: "Merus N.V. Corporate Slide Presentation as of January 9, 2023",
"Merus N.V. Corporate Slide Presentation as of January 9, 2023"
01/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, effective as of January 1, 2023, by and between Merus US, Inc. and Peter B. Silverman",
"Employment Agreement, effective as of January 1, 2023, by and between Merus US, Inc. and Peter B. Silverman"
05/31/2022 8-K Quarterly results
01/25/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145 UTRECHT, The Netherlands and CAMBRIDGE, Mass., January 25, 2022 — Merus N.V. , a clinical-stage oncology company developing innovative, full-length multispecific antibodies , today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology. “Shannon will be instrumental in advancing Merus' mission to become a commercial-stage company, further advancing the strategy for our lead clinical program, zenocutuzumab for neuregulin 1 fusion cancer and developing our commercial approach for our pip..."
11/08/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, between Merus N.V. and Jefferies LLC and SVB Leerink LLC, as representatives of the underwriters named therein",
"Opinion of NautaDutilh N.V"
05/28/2021 8-K Quarterly results
01/22/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, between Merus N.V. and Jefferies LLC and SVB Leerink LLC, as representatives of the underwriters named therein",
"Opinion of NautaDutilh N.V"
01/20/2021 8-K Termination of a Material Definitive Agreement  Interactive Data
01/19/2021 8-K Quarterly results
09/02/2020 8-K Investor presentation
Docs: "Merus N.V. Corporate Slide Presentation as of September 2, 2020"
08/06/2020 8-K Quarterly results
07/06/2020 8-K Quarterly results
05/19/2020 8-K Investor presentation
Docs: "Merus N.V. Corporate Slide Presentation as of May 19, 2020",
"Merus N.V. Corporate Slide Presentation as of May 19, 2020"
04/16/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/13/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : April 7, 2020 MERUS N.V. The Netherlands 001-37773 Not Applicable Yalelaan 62 3584 CM Utrecht The Netherlands +31 85 016 2500 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Ex..."
03/17/2020 8-K Quarterly results
03/12/2020 8-K Quarterly results
01/09/2020 8-K Investor presentation
Docs: "Merus N.V. Corporate Slide Presentation as of January 9, 2020",
"Merus N.V. Corporate Slide Presentation as of January 9, 2020"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy